|
Dec 2006
Insulin resistance and hepatitis C.
Boehringer Ingelheim: entering the hepatitis C arena
Transplantation and viral hepatitis: major
progress
Screening, diagnosis, and treatment of
hepatitis among homeless, substance abusing women
AASLD 2006 - Complications of Cirrhosis and
Portal Hypertension-Variceal Bleeding: Clinical Insights and
Implications for Practice
Impact of cirrhosis on outcomes in trauma.
Oglufanide Tested as Potential Hepatitis C
Treatment
Hepatitis C Toothbrush Contamination
New Method for Improving HCV/HIV Co-Infection
Response
Implications of HCV in Liver Transplantation
Hepatitis C and the damage done, part II
Updated Results from Patients Receiving
Standard HCV Therapy Following Telaprevir
HCV Treatment Response Persists after Kidney
Transplantation
Different Signaling Pathways in Patients with
Hepatitis B and C
Nov 2006
Blood or liver problems usually associated with jaundice
Approaches to Liver Biopsy Techniques-Revisited
Does Coffee Drinking Protect Cirrhotic Patients against
Hepatocellular Carcinoma
Coverage of 57th Annual Meeting
of the American Association for the Study of Liver Disease
AASLD Coverage From : NATAP
http://www.natap.org/
From: HCV Advocate
AASLD 2006 Onsite Coverage
Oct 2006
Routine Laboratory Data Can Help
Predict Advanced Liver Fibrosis in HIV-HCV Coinfected Patients
Baseline viral load (400,000 IU/mL) as a
predictor of SVR rate with peginterferon alfa-2a (40KD) (PEGASYS)
plus ribavirin (COPEGUS) in HCV/HIV Coinfected in Apricot Study
Non-viral Factors Associated with HCV
Recurrence after Liver Transplantation
Hepatitis C Treatment after Liver
Transplantation
Life Expectancy after Liver Transplantation
Heavy smoking and liver
4-Week Response to Anti-HCV Treatment Predicts
Outcome
HCV Polymerase Inhibitor R-1626 Advances to
Phase II Study
Liver Fibrosis in Women with Chronic
Hepatitis C
The Nucleoside Inhibitor MK-0608 Mediates
Suppression of HCV Replication for >30 Days in Chronically Infected
Chimpanzees - 10/02/06
HCV Drug Pipeline
updated October 5,
2006
Immunological Control of Hepatitis C Virus
during Acute Infection
HCV Core Protein Linked to Immune Evasion in
Liver Cells
Organ Transplant Centers Face Federal Scrutiny
Liver Toxicity Associated with Ritonavir-boosted
Tipranavir
World Hepatitis Awareness Day
Women Given Liver Transplants Outlive Male
Recipients By Around 4 Years
16-week Treatment May Be Adequate for Genotype
2 Hepatitis C Patients
IP-10 Levels Predict Treatment Response in
Patients with Hepatitis C
Social and Behavioral Factors Associated with
HCV Transmission in Injection Drug Users
LDL Receptor Levels, Alcohol Consumption, and
HCV Viral Load in Hepatitis C Patients
Causes of Death after Diagnosis of Hepatitis B
or C
Viral Clearance and Disease Progression in
Siblings with Hepatitis C
Spleen Removal Can Help Hepatitis C Patients
with Cirrhosis Tolerate Treatment
Sept 2006
Insulin resistance and HCV: Will new knowledge
modify clinical management? -
09/21/06
GAY MEN AND HEP C
-
NIM811, a Cyclophilin Inhibitor, Exhibits
Potent In Vitro Activity against Hepatitis C Virus Alone or in
Combination with Alpha Interferon
ViroPharma Announces Positive Data From Phase
1b Combination Study Of HCV-796 And Pegylated Interferon In
Hepatitis C Patients -
Hispanics Have More Aggressive Liver Disease
in LA County Hepatitis Clinic
DDW 2006: Conference
Highlights – Part 3
HealthWise: Dietary Supplements
Statins: A New Therapy for Hepatitis C?
Hepatotoxicity From Statin Therapy
Statins May Trigger Autoimmune Hepatitis
Excerpt: MANAGEMENT OF HEPATITIS C BY THE
PRIMARY CARE PROVIDER: MONITORING GUIDELINES
No Link Found between Hepatitis C Infection
and Heart Attacks
Can Hepatitis C Be Transmitted by Sharing
Toothbrushes?
Mutation Patterns and Genotypes Associated
with Hepatocellular Carcinoma in HBV/HCV Coinfected Patients
Vaccination against hepatitis A and B:
developments, deployment and delusions
Hepatitis In Primary Care:What Physician
Assistants Can Do To Help Save Million
72-Week Treatment More Effective than 48
Weeks for Patients with Detectable HCV Viral Load at Week 4
No Evidence of Hepatitis C Virus
Recombination in Superinfected Patients
ViroPharma and Wyeth Announce Achievement
of "Proof of Concept" Milestone for HCV-796, Phase II Study to Begin
Soon
Study Confirms Poorer Interferon Treatment
Response in African Americans
Aug 2006
HealthWise: Healthy Living with HCV Series
Part 4 — Tipping the Scales towards Successful Weight Loss
New HCV Antivirals and Drug Resistance
DDW 2006: Conference Highlights – Part 2
Efficacy of Low-dose Peg-Intron
HCV Death Rate Doubles Among IDUs in Last 5
Years
Peregrine's Final HCV Phase 1a Study Results
Accepted for Oral Presentation at AASLD Annual Meeting
-
Distribution of Hepatitis C Virus Genotypes
and Viral Load Levels in the U.S.
Cost effectiveness of interferon or
peginterferon with ribavirin for histologically mild chronic
hepatitis C -
Is HCV Infection Associated with Liver
Steatosis in Children?
Gene Response to Interferon Therapy for
Hepatitis C Differs by Race
Study Confirms Poorer Interferon Treatment
Response in African Americans
Relation between LDL Cholesterol Levels and
Hepatitis C Treatment Outcomes
Predictors of Sexual Transmission of HCV in
Gay Men
Non-invasive Assessment of Liver
Fibrosis in Patients with Hepatitis C
Long-term Effect of
Interferon/Ribavirin on Incidence of Hepatocellular Carcinoma
Cost effectiveness of interferon or
peginterferon with ribavirin for histologically mild chronic
hepatitis C -
72 Weeks Pegasys/RBV Improves SVR for When HCV-RNA
is Detectable at Week 4 -
Diabetes is Associated with Hepatic
Encephalopathy in Patients with HCV-Related Cirrhosis
Pegylated Interferon Plus Ribavirin Therapy in
Patients with HCV Recurrence after Liver Transplantation
Thyroid Dysfunction in Chronic
Hepatitis C Patients Treated with Interferon/Ribavirin
Pegasys/RBV in
African-Americans -
Hepatic
fibrosis in Hispanics
Hepatitis C Virus Detection Using HCV
RNA Qualitative (TMA) Testing in the HALT-C Trial
HCV RNA detection by TMA during the hepatitis
C antiviral long-term treatment against cirrhosis (Halt-C) trial
A low-carbohydrate diet rapidly and
dramatically reduces intrahepatic triglyceride content
CDC Study on HCV Risk Transmission &
Tattoos/Body Piercing, Snorting Drugs
-
Age Alone Does Not Affect Outcome of Liver
Transplant in Elderly
Genetic Variation
and Hepatitis C
New HCV Antivirals and Drug Resistance
FDA Warns About Eating Raw Wash. Oysters
Effect of Tattooing, Body Piercing and
Intranasal Drug Use on Risk of HCV & HBV
Interferon Enhancer Drug EMZ702 Study + PegIFN/RBV
-
Natural History of Liver Cirrhosis Due to
Hepatitis C
July 2006
Lifestyle changes and beliefs regarding
disease severity in patients with chronic hepatitis C.
Stuck With Hepatitis
Hispanics with Chronic Hepatitis C May Develop
More Advanced Fibrosis
Detection of HCV RNA in the Livers of Patients
with "Undetectable" Viral Load and Normal ALT
Sexual Problems in Men with Hepatitis C
Extrahepatic replication of HCV: Insights into
clinical manifestations and biological consequences
-
The Role of CD4 and CD8 T-Cells in Spontaneous
Clearance of Hepatitis C Virus
Statin Drugs Inhibit HCV in vitro
Smoking May Worsen Liver Fibrosis in Patients
with Hepatitis C
Retreatment and Long-Term Follow-Up of
Nonresponders
Extra-Strength Acetaminophen Can Cause Liver
Inflammation in People without Liver Disease
Impact of Alcohol Use on Hepatitis C Treatment
Outcomes and Quality of Life
Natural History of Chronic Hepatitis C in
Patients Age 65 and Older
Hepatitis Induced by Noni Juice from Morinda
citrifolia
CLINICAL MANIFESTATIONS OF LIVER DISEASE
Phase 2 Study of VX-950, Pegasys, and Copegus
in Hepatitis C- study sites
Hepatic Steatosis Is Associated with Fibrosis,
Nucleoside Analogue Use, and Hepatitis C Virus Genotype 3 Infection
in HIV-Seropositive Patients: Steatosis was present in 69% of
patients
BREASTFEEDING & HCV TRANSMISSION
Drug Resistance Wksp:
Coffee, Cirrhosis, and Transaminase Enzymes
|
